Request Clinical Starter Kits for Your Patients Today! Request Now

 Cholesterol and Lipid Metabolism STUDIES

ENDUR-ACIN® is an effective treatment for hyperlipidemia in patients with ischemic heart disease, especially if fibrates are contraindicated

Highlights ENDUR-ACIN® is an effective treatment for hyperlipidemia in patients with ischemic heart disease, especially if fibrates are contraindicated. Summary This comparison study explores the relative efficacy of long-term use...
on February 25, 2020

ENDUR-ACIN® is a safe and effective treatment for dyslipidemia, systematic review shows

Highlights ENDUR-ACIN® significantly improves blood lipids in patients with dyslipidemia Effective dosage range is 1,500 to 2,000 mg/day Mean LDL cholesterol reduction in the range of 16-21% Good safety profile...
on February 25, 2020

ENDUR-ACIN® is a clinically effective therapy for dyslipidemia, study shows

Highlights ENDUR-ACIN® decreases LDL-cholesterol by 27% and increases HDL-cholesterol by 17%, on average Effective amounts of ENDUR-ACIN® range from 1,500-2,000 mg/day ENDUR-ACIN® therapeutic benefits for hypercholesterolemia and/or low HDL-cholesterol. Summary...
on February 25, 2020

ENDUR-ACIN® improves total and HDL-cholesterol in patients with coronary artery disease, study shows

Highlights ENDUR-ACIN® improves blood cholesterol in hyperlipidemic patients with coronary artery disease 13% reduction in total cholesterol, on average 31% increase in HDL cholesterol, on average Well tolerated with only...
on February 25, 2020

ENDUR-ACIN® improves blood lipids and transport proteins in familial hypercholesterolemia, study shows

Highlights ENDUR-ACIN® improves blood lipids in patients with Types IIa and IIb hyperlipoproteinemias Improvements in lipid transport proteins apo-A1 and apo-B also seen Treatment reported to be well tolerated by...
on February 25, 2020
"